C-Bridge Capital, BioBAY Lead $38M Series A Round In Biopharmaceutical Service Firm CMAB BioPharm


Chinese private equity firm C-Bridge Capital has teamed up with Suzhou bio-medical and medical high-tech park BioBAY in leading a US$38 million series A round in CMAB BioPharm, a contract development and manufacturing organization (CDMO) providing comprehensive pharmaceutical services to biopharma companies. Jianqiao Capital and Qianhai Fund of Funds also participated in the round, the company announced today. Located at BioBAY in Suzhou, CMAB BioPharm provides good manufacturing practice (GMP) services, including cell line development, GMP production and regulatory support, …

C-Bridge Capital, BioBAY Lead $38M Series A Round In Biopharmaceutical Service Firm CMAB BioPharm appeared first on China Money Network.


Print Print | Email Email | Category: China News

Sorry, comments are closed at this time.